Literature DB >> 24256358

The development and validation of an UHPLC-MS/MS method for the rapid quantification of the antiretroviral agent dapivirine in human plasma.

Lauren A Seserko1, Joshua F Emory, Craig W Hendrix, Mark A Marzinke.   

Abstract

BACKGROUND: Dapivirine is a non-nucleoside reverse transcriptase inhibitor designed to prevent HIV-1 viral replication and subsequent propagation. A sensitive method is required to quantify plasma concentrations to assess drug efficacy.
RESULTS: Dapivirine-spiked plasma was combined with acetonitrile containing deuterated IS and was processed for analysis. The method has an analytical measuring range from 20 to 10,000 pg/ml. For the LLOQ, low, mid and high QCs, intra- and inter-assay precision (%CV) ranged from 5.58 to 13.89% and 5.23 to 13.36%, respectively, and intra- and inter-day accuracy (% deviation) ranged from -5.61 to 0.75% and -4.30 to 6.24%, respectively.
CONCLUSION: A robust and sensitive LC-MS/MS assay for the high-throughput quantification of the antiretroviral drug dapivirine in human plasma was developed and validated following bioanalytical validation guidelines. The assay meets criteria for the analysis of samples from large research trials.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24256358      PMCID: PMC4104354          DOI: 10.4155/bio.13.256

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  28 in total

1.  The future of HIV prevention: prospects for an effective anti-HIV microbicide.

Authors:  Jeremy Nuttall; Joseph Romano; Karen Douville; Caroline Galbreath; Annaléne Nel; William Heyward; Mark Mitchnick; Saul Walker; Zeda Rosenberg
Journal:  Infect Dis Clin North Am       Date:  2007-03       Impact factor: 5.982

2.  Matrix effect in quantitative LC/MS/MS analyses of biological fluids: a method for determination of finasteride in human plasma at picogram per milliliter concentrations.

Authors:  B K Matuszewski; M L Constanzer; C M Chavez-Eng
Journal:  Anal Chem       Date:  1998-03-01       Impact factor: 6.986

3.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

Authors:  Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

4.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Authors:  Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

5.  Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women.

Authors:  Annalene Nel; Shanique Smythe; Katherine Young; Karl Malcolm; Clare McCoy; Zeda Rosenberg; Joseph Romano
Journal:  J Acquir Immune Defic Syndr       Date:  2009-08-01       Impact factor: 3.731

Review 6.  Recent advances in the development of next generation non-nucleoside reverse transcriptase inhibitors.

Authors:  Christine M Tarby
Journal:  Curr Top Med Chem       Date:  2004       Impact factor: 3.295

7.  Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring.

Authors:  J Romano; B Variano; P Coplan; J Van Roey; K Douville; Z Rosenberg; M Temmerman; H Verstraelen; L Van Bortel; S Weyers; M Mitchnick
Journal:  AIDS Res Hum Retroviruses       Date:  2009-05       Impact factor: 2.205

8.  Development and validation of a HPLC method for the assay of dapivirine in cell-based and tissue permeability experiments.

Authors:  José das Neves; Bruno Sarmento; Mansoor Amiji; Maria Fernanda Bahia
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2012-11-02       Impact factor: 3.205

9.  In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides.

Authors:  Yven Van Herrewege; Jo Michiels; Jens Van Roey; Katrien Fransen; Luc Kestens; Jan Balzarini; Paul Lewi; Guido Vanham; Paul Janssen
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

10.  Preexposure prophylaxis for HIV infection among African women.

Authors:  Lut Van Damme; Amy Corneli; Khatija Ahmed; Kawango Agot; Johan Lombaard; Saidi Kapiga; Mookho Malahleha; Fredrick Owino; Rachel Manongi; Jacob Onyango; Lucky Temu; Modie Constance Monedi; Paul Mak'Oketch; Mankalimeng Makanda; Ilse Reblin; Shumani Elsie Makatu; Lisa Saylor; Haddie Kiernan; Stella Kirkendale; Christina Wong; Robert Grant; Angela Kashuba; Kavita Nanda; Justin Mandala; Katrien Fransen; Jennifer Deese; Tania Crucitti; Timothy D Mastro; Douglas Taylor
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

View more
  17 in total

1.  Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women.

Authors:  Jared M Baeten; Thesla Palanee-Phillips; Elizabeth R Brown; Katie Schwartz; Lydia E Soto-Torres; Vaneshree Govender; Nyaradzo M Mgodi; Flavia Matovu Kiweewa; Gonasagrie Nair; Felix Mhlanga; Samantha Siva; Linda-Gail Bekker; Nitesha Jeenarain; Zakir Gaffoor; Francis Martinson; Bonus Makanani; Arendevi Pather; Logashvari Naidoo; Marla Husnik; Barbra A Richardson; Urvi M Parikh; John W Mellors; Mark A Marzinke; Craig W Hendrix; Ariane van der Straten; Gita Ramjee; Zvavahera M Chirenje; Clemensia Nakabiito; Taha E Taha; Judith Jones; Ashley Mayo; Rachel Scheckter; Jennifer Berthiaume; Edward Livant; Cindy Jacobson; Patrick Ndase; Rhonda White; Karen Patterson; Donna Germuga; Beth Galaska; Katherine Bunge; Devika Singh; Daniel W Szydlo; Elizabeth T Montgomery; Barbara S Mensch; Kristine Torjesen; Cynthia I Grossman; Nahida Chakhtoura; Annalene Nel; Zeda Rosenberg; Ian McGowan; Sharon Hillier
Journal:  N Engl J Med       Date:  2016-02-22       Impact factor: 91.245

2.  Development and bioanalytical validation of a liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma.

Authors:  Joshua F Emory; Lauren A Seserko; Mark A Marzinke
Journal:  Clin Chim Acta       Date:  2014-02-19       Impact factor: 3.786

3.  Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial.

Authors:  Beatrice A Chen; Lori Panther; Mark A Marzinke; Craig W Hendrix; Craig J Hoesley; Ariane van der Straten; Marla J Husnik; Lydia Soto-Torres; Annalene Nel; Sherri Johnson; Nicola Richardson-Harman; Lorna K Rabe; Charlene S Dezzutti
Journal:  J Acquir Immune Defic Syndr       Date:  2015-11-01       Impact factor: 3.731

4.  Validation and implementation of an ultrasensitive liquid chromatographic-tandem mass spectrometric (LC-MS/MS) assay for dapivirine quantitation in breast milk.

Authors:  Madhuri Manohar; Mark A Marzinke
Journal:  Clin Biochem       Date:  2019-12-13       Impact factor: 3.281

5.  Implementation of a Novel Adherence Monitoring Strategy in a Phase III, Blinded, Placebo-Controlled, HIV-1 Prevention Clinical Trial.

Authors:  Marla J Husnik; Elizabeth R Brown; Mark Marzinke; Edward Livant; Thesla Palanee-Phillips; Craig W Hendrix; Flavia Matovu Kiweewa; Gonasagrie Nair; Lydia E Soto-Torres; Katie Schwartz; Sharon L Hillier; Jared M Baeten
Journal:  J Acquir Immune Defic Syndr       Date:  2017-11-01       Impact factor: 3.731

6.  Brief Report: Dapivirine Vaginal Ring Use Does Not Diminish the Effectiveness of Hormonal Contraception.

Authors:  Jennifer E Balkus; Thesla Palanee-Phillips; Krishnaveni Reddy; Samantha Siva; Ishana Harkoo; Clemensia Nakabiito; Kenneth Kintu; Gonasangrie Nair; Catherine Chappell; Flavia Matovu Kiweewa; Samuel Kabwigu; Logashvari Naidoo; Nitesha Jeenarain; Mark Marzinke; Lydia Soto-Torres; Elizabeth R Brown; Jared M Baeten
Journal:  J Acquir Immune Defic Syndr       Date:  2017-10-01       Impact factor: 3.731

7.  Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B).

Authors:  Jennifer A Robinson; Mark A Marzinke; Rahul P Bakshi; Edward J Fuchs; Christine L Radebaugh; Wutyi Aung; Hans M L Spiegel; Jenell S Coleman; Lisa C Rohan; Craig W Hendrix
Journal:  AIDS Res Hum Retroviruses       Date:  2016-12-13       Impact factor: 2.205

8.  Phase 2a Safety, Pharmacokinetics, and Acceptability of Dapivirine Vaginal Rings in US Postmenopausal Women.

Authors:  Beatrice A Chen; Jingyang Zhang; Holly M Gundacker; Craig W Hendrix; Craig J Hoesley; Robert A Salata; Charlene S Dezzutti; Ariane van der Straten; Wayne B Hall; Cindy E Jacobson; Sherri Johnson; Ian McGowan; Annalene M Nel; Lydia Soto-Torres; Mark A Marzinke
Journal:  Clin Infect Dis       Date:  2019-03-19       Impact factor: 9.079

9.  Dual quantification of dapivirine and maraviroc in cervicovaginal secretions from ophthalmic tear strips and polyester-based swabs via liquid chromatographic-tandem mass spectrometric (LC-MS/MS) analysis.

Authors:  Teresa L Parsons; Joshua F Emory; Lauren A Seserko; Wutyi S Aung; Mark A Marzinke
Journal:  J Pharm Biomed Anal       Date:  2014-06-21       Impact factor: 3.935

10.  A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film.

Authors:  Katherine E Bunge; Charlene S Dezzutti; Lisa C Rohan; Craig W Hendrix; Mark A Marzinke; Nicola Richardson-Harman; Bernard J Moncla; Brid Devlin; Leslie A Meyn; Hans M L Spiegel; Sharon L Hillier
Journal:  J Acquir Immune Defic Syndr       Date:  2016-04-15       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.